CIS Expands Offerings with the Launch of Emergent BioPharma Insights™, a Commercialization Solution Designed for Clinical Stage Companies

Online, November 14, 2013 (Newswire.com) - Compliance Implementation Services (CIS), a leading life sciences consulting firm, today announced the launch of Emergent BioPharma Insights™, a commercialization solution designed to help clinical
stage companies prepare for and achieve successful commercialization. Neil DeHenes is the practice lead for this solution, which provides holistic commercialization consulting services, strategy development and support for commercial operations during pre- and post-launch.

"As clinical stage companies progress through phase II and III studies and head towards product launch, they typically have a high demand for sophisticated commercialization analysis and strategy consulting services. Our holistic commercialization solution analyzes, develops and implements a customized strategy tailored to a company's product and business needs," said DeHenes. "Another key focus is advising company executives who are preparing to launch their first product and are undecided about which commercial path they should take. We help these executives understand their product's market potential, profitability and how this relates to the baseline costs and financial liabilities of commercialization."

"CIS' commercialization services build upon our established strengths in compliance and risk management, contracting and government programs. With the addition of Neil and his extensive experience at Cardinal Health working with manufacturers to launch products, we built a team that leverages the strengths and experience of our
industry experts and proprietary systems to help clinical stage companies reach their full potential," said Jim Collins, CFO and Co-Founder.

In connection with the launch of Emergent BioPharma Insights™, CIS' commercial experts are attending PABio's Life Sciences Future conference taking place today at the Philadelphia Convention Center. CIS' Judy Fox, Director, Transparency Compliance, is one of the featured "Short Takes" speakers and will speak on the impact of the Sunshine Act on physician relationships.

A case study outlining how CIS helped a clinical stage company launch a virtual commercial model may be found at http://cis-partners.com/wp-content/uploads/2013/04/CC0313_Virtual_Model_Case_Study_web.pdf.

About Compliance Implementation Services (CIS)
Compliance Implementation Services (CIS) is a consulting firm focused on helping life sciences clients proactively manage complex compliance requirements. We offer a broad portfolio of services and solutions that expand deep into the clinical, manufacturing and commercial disciplines and that align with our clients' strategic priorities and business operations. CIS continually provides leadership, global regulatory knowledge, industry experience and a problem-solving culture that responds to today's compliance and commercial challenges. For more information, visit www.cis-partners.com.

About CIS' Emergent BioPharma Insights™
To support the unique needs of clinical stage companies, CIS has designed a program called Emergent Biopharma Insights™ that provides valuable training, up-to-date regulatory guidance, insights and best practices at each stage in the product lifecycle, from pre-launch through launch and commercialization. The program is designed to help companies achieve successful commercialization by educating companies on the processes needed for a compliant business and the options available for commercial success. For more information, visit the Emergent BioPharma Insights™ Online Resource Center.